Jpmorgan Chase & CO Pliant Therapeutics, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding PLRX
# of Institutions
163Shares Held
63.9MCall Options Held
481KPut Options Held
105K-
Deep Track Capital, LP Greenwich, CT5.97MShares$86.5 Million2.11% of portfolio
-
Black Rock Inc. New York, NY4.97MShares$72 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.6MShares$66.7 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.44MShares$49.8 Million0.0% of portfolio
-
First Light Asset Management, LLC Edina, MN3.4MShares$49.3 Million3.33% of portfolio
About PLIANT THERAPEUTICS, INC.
- Ticker PLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,682,000
- Market Cap $705M
- Description
- Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...